- Corporate Officers - A
- Alles Mark J
Insider Trading History of Alles Mark J
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Alles Mark J since 2012.
This trader's CIK number is 1538897.
At the time of last reporting, Alles Mark J was the Director of Syros Pharmaceuticals, Inc.. (stock ticker symbol SYRS).
Also see all insider trading activities at Syros Pharmaceuticals, Inc..
Note that in the past
Alles Mark J also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Biomarin Pharmaceutical Inc (BMRN) by Alles Mark J
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | BMRN | 3,625 | $314,468 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Syros Pharmaceuticals, Inc. (SYRS) by Alles Mark J
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | SYRS | 0 | $0 | 0 | $0 | 2,666 | $0 |
| 2020 | SYRS | 10,000 | $88,590 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Celgene Corp /de/ (CELG) by Alles Mark J
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | CELG | 0 | $0 | 0 | $0 | 49,417 | $0 |
| 2018 | CELG | 4,468 | $399,378 | 0 | $0 | 19,712 | $0 |
| 2017 | CELG | 0 | $0 | 0 | $0 | 8,750 | $0 |
| 2016 | CELG | 0 | $0 | 0 | $0 | 24,120 | $0 |
| 2015 | CELG | 0 | $0 | 117,099 | $14,131,156 | 166,568 | $6,112,631 |
| 2013 | CELG | 0 | $0 | 101,406 | $14,904,981 | 133,766 | $6,513,603 |
| 2012 | CELG | 0 | $0 | 0 | $0 | 3,056 | $0 |
Insider trading activities at 3 companies by Alles Mark J:
1. Biomarin Pharmaceutical Inc (BMRN)
2. Syros Pharmaceuticals, Inc. (SYRS)
3. Celgene Corp /de/ (CELG)
Table 1. Insider trading of Biomarin Pharmaceutical Inc (BMRN) by Alles Mark J
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-10-31 | BMRN | Buy | 3,625 | 86.75 | 314,468 |
Table 2. Insider trading of Syros Pharmaceuticals, Inc. (SYRS) by Alles Mark J
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-09-16 | SYRS | Option Ex | 2,666 | .00 | 0 |
| 2020-05-13 | SYRS | Buy | 10,000 | 8.86 | 88,590 |
Table 3. Insider trading of Celgene Corp /de/ (CELG) by Alles Mark J
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-05-02 | CELG | Option Ex | 15,608 | .00 | 0 |
| 2019-03-01 | CELG | Option Ex | 33,809 | .00 | 0 |
| 2018-12-16 | CELG | Option Ex | 8,929 | .00 | 0 |
| 2018-05-09 | CELG | Buy | 1,208 | 82.60 | 99,784 |
| 2018-05-04 | CELG | Option Ex | 3,500 | .00 | 0 |
| 2018-02-17 | CELG | Option Ex | 7,283 | .00 | 0 |
| 2018-02-08 | CELG | Buy | 3,260 | 91.90 | 299,594 |
| 2017-12-19 | CELG | Option Ex | 4,550 | .00 | 0 |
| 2017-07-28 | CELG | Option Ex | 4,200 | .00 | 0 |
| 2016-12-02 | CELG | Option Ex | 6,560 | .00 | 0 |
| 2016-12-02 | CELG | Option Ex | 6,560 | .00 | 0 |
| 2016-04-29 | CELG | Option Ex | 11,000 | .00 | 0 |
| 2015-12-17 | CELG | Option Ex | 11,670 | .00 | 0 |
| 2015-04-30 | CELG | Option Ex | 11,200 | .00 | 0 |
| 2015-03-01 | CELG | Option Ex | 8,334 | .00 | 0 |
| 2015-02-12 | CELG | Option Ex | 27,505 | 45.16 | 1,242,043 |
| 2015-02-06 | CELG | Option Ex | 107,859 | 45.16 | 4,870,588 |
| 2015-02-06 | CELG | Sale | 117,099 | 120.68 | 14,131,156 |
| 2013-12-27 | CELG | Option Ex | 7,777 | .00 | 0 |
| 2013-11-01 | CELG | Option Ex | 10,000 | .00 | 0 |
| 2013-08-02 | CELG | Sale | 5,000 | 146.47 | 732,335 |
| 2013-07-31 | CELG | Sale | 96,406 | 147.01 | 14,172,646 |
| 2013-08-02 | CELG | Option Ex | 15,000 | 66.49 | 997,349 |
| 2013-07-31 | CELG | Option Ex | 96,406 | 57.22 | 5,516,254 |
| 2013-04-13 | CELG | Option Ex | 4,583 | .00 | 0 |
| 2012-04-14 | CELG | Option Ex | 3,056 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Alles Mark J
(Director of Syros Pharmaceuticals, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.